Categories Earnings, Health Care

Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot

— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.

— Revenue rose 16% to $69.6 million vs. $93.15 million expected.

Earnings Update by AlphaStreet

— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.

— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.

— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.

— AKBA stock dipped more than 5% in the pre-market trading session.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Key highlights from Halliburton (HAL) Q1 2021 earnings results

Halliburton Company (NYSE: HAL) reported first-quarter 2021 earnings results today. Total revenue decreased by 31% to $3.45 billion from $5.03 billion year on year. The company had a net income

Key highlights from Intuitive Surgical (ISRG) Q1 2021 earnings results

Intuitive Surgical, Inc. (NASDAQ: ISRG) reported first quarter 2021 earnings results today. Revenues increased 18% year-over-year to $1.29 billion, driven by growth in da Vinci procedures and system placements. GAAP net income

Earnings Infographic: Netflix (NFLX) subscriber growth slows; Q1 results beat

Netflix, Inc. (NASDAQ: NFLX) Tuesday said its first-quarter 2021 earnings more than doubled. Both revenues and profit topped the Street view, but the streaming giant's subscriber growth decelerated. At the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top